Scholar Rock's second quarter saw the relatively early-stage company post no revenue and a net loss of over $110 million, or ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Scholar Rock Holding SRRK -4.80% + Free Alerts has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

Review the current Scholar Rock Holding Corp (SRRK:XNAS) dividend yield and history to decide if SRRK is the best investment for you.

Queen's legendary guitarist, Brian May, known for iconic solos, also holds a PhD in astrophysics. His thesis, completed in ...

Norman Finkelstein, a political scientist and activist known for his fiery on-air criticisms of Israel’s ongoing genocide in ...

Quorum breaking has a long history in Texas; however, Gov. Greg Abbott's Tuesday petition to the state's Supreme Court is ...

Anyone who’s attended college knows juggling a hefty schedule and making time for a social life can be hard, but one UA ...

The Flatwater Shakespeare Company is staging "Romeo and Juliet" — with a punk-rock twist. The play opens Thursday at the ...